Sera Prognostics, Inc. (SERA) Stock Price & Analysis
Sera Prognostics, Inc. (SERA) fell 5.53% to USD 2.05 as of July 25, 2026 at 19:41 UTC, according to Nexqual real-time market data.
SERA last closed at USD 2.17; the session ranged USD 1.99–2.25 on volume of 18,633 shares. Market capitalization is $80.28M, with a 52-week range of USD 1.56–3.95 (NGM). Source: Nexqual, July 25, 2026 at 19:41 UTC.
Key Statistics (as of July 25, 2026 at 19:41 UTC)
| Price | USD 2.05 |
|---|---|
| Change | ▼ 5.53% (down) |
| Previous Close | USD 2.17 |
| Open | USD 2.17 |
| Day Range | USD 1.99 – 2.25 |
| 52-Week Range | USD 1.56 – 3.95 |
| Volume | 18,633 shares |
| Market Cap | $80.28M |
| Exchange | NGM |
Technical Analysis (SERA)
Nexqual's technical model rates SERA "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 19:41 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 47.16 (neutral) |
| vs SMA50 | Above (USD 1.98) |
| MACD | 0.05 (positive) |
Analyst Ratings (SERA)
Wall Street analysts rate SERA "Strong Buy" based on 2 analysts, with a mean price target of USD 5.5 (range USD 5–6), per Nexqual as of July 25, 2026 at 19:41 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 5.5 |
| High Target | USD 6 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (SERA)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.16 |
| Revenue Estimate | $50,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.17 vs est -0.17 ▲ beat |
| 2025-12-31 | USD -0.16 vs est -0.19 ▲ beat |
| 2025-09-30 | USD -0.16 vs est -0.21 ▲ beat |
| 2025-06-30 | USD -0.16 vs est -0.24 ▲ beat |
Source: Nexqual, July 25, 2026 at 19:41 UTC.
Financials & Fundamentals (SERA)
| Total Revenue | $57,000 |
|---|---|
| Revenue Growth (YoY) | -63.20% |
| Gross Margin | -191.23% |
| Operating Margin | -66857.14% |
| Profit Margin | +0.00% |
| ROE | -39.58% |
| Debt / Equity | 3.71 |
| Current Ratio | 2.12 |
| Total Cash | $47.40M |
| Total Debt | $2.50M |
| Free Cash Flow | $-18.90M |
Source: Nexqual, July 25, 2026 at 19:41 UTC.
Financial Health Score (SERA)
Nexqual rates Sera Prognostics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 19:41 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $47M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$19M, burning cash |
| Efficiency | Critical — ROE -40%, ROA -21.6% |
Ownership (SERA)
| Insider Ownership | +11.89% |
|---|---|
| Institutional Ownership | +51.57% |
| Shares Outstanding | 38.19M |
| Float | 27.47M |
| Short % of Float | +0.78% |
Source: Nexqual, July 25, 2026 at 19:41 UTC.
Leadership (SERA)
Sera Prognostics, Inc. is led by Zhenya Lindgardt (age 51), President, CEO & Director, per Nexqual as of July 25, 2026 at 19:41 UTC.
| President, CEO & Director | Zhenya Lindgardt (age 51) |
|---|---|
| Chief Scientific Officer | John J. Boniface (age 63) |
| Executive Director | Gregory C. Critchfield M.D., M.S. (age 72) |
| Chief Financial Officer | Austin Aerts (age 38) |
Major Backers & Investors (SERA)
Notable institutional backers of Sera Prognostics, Inc. include Baker Bros. Advisors, LP, Whetstone Capital Advisors, LLC, Aberdeen Group plc, according to Nexqual as of July 25, 2026 at 19:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Baker Bros. Advisors, LP | 14.4% |
| Whetstone Capital Advisors, LLC | 8.66% |
| Aberdeen Group plc | 6.68% |
| abrdn Healthcare Investors | 6.68% |
| Vivo Capital, LLC | 4.32% |
| CAPTRUST Financial Advisors | 1.41% |
| Fidelity | 0.75% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.27% |
| Geode Capital | 0.95% |
| BlackRock | 0.72% |
Source: Nexqual, July 25, 2026 at 19:41 UTC.
From Sera Prognostics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States.
- The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation.
- It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INAB | IN8bio, Inc. | USD 1.2 | ▼ 2.44% |
| NEXI | NexImmune, Inc. | USD 0 | ▲ 0% |
| TCRX | TScan Therapeutics, Inc. | USD 0.79 | ▼ 11.78% |
| SGHT | Sight Sciences, Inc. | USD 4.91 | ▼ 2.39% |
| AIMD | Ainos, Inc. | USD 1.4 | ▼ 9.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 19:41 UTC. This page is informational and not investment advice.